- Home
- LTRN vs HOWL Comparison
LTRN vs HOWL Comparison
Compare LTRN & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LTRN
- HOWL
- Stock Information
- Founded
- LTRN 2013
- HOWL 2017
- Country
- LTRN United States
- HOWL United States
- Employees
- LTRN N/A
- HOWL N/A
- Industry
- LTRN Biotechnology: Pharmaceutical Preparations
- HOWL Biotechnology: Pharmaceutical Preparations
- Sector
- LTRN Health Care
- HOWL Health Care
- Exchange
- LTRN Nasdaq
- HOWL Nasdaq
- Market Cap
- LTRN 37.2M
- HOWL 37.9M
- IPO Year
- LTRN 2020
- HOWL 2021
- Fundamental
- Price
- LTRN $4.10
- HOWL $0.98
- Analyst Decision
- LTRN Strong Buy
- HOWL Strong Buy
- Analyst Count
- LTRN 1
- HOWL 3
- Target Price
- LTRN $25.00
- HOWL $8.33
- AVG Volume (30 Days)
- LTRN 37.1K
- HOWL 263.3K
- Earning Date
- LTRN 05-15-2025
- HOWL 05-08-2025
- Dividend Yield
- LTRN N/A
- HOWL N/A
- EPS Growth
- LTRN N/A
- HOWL N/A
- EPS
- LTRN N/A
- HOWL N/A
- Revenue
- LTRN N/A
- HOWL $1,143,000.00
- Revenue This Year
- LTRN N/A
- HOWL N/A
- Revenue Next Year
- LTRN N/A
- HOWL $733.33
- P/E Ratio
- LTRN N/A
- HOWL N/A
- Revenue Growth
- LTRN N/A
- HOWL N/A
- 52 Week Low
- LTRN $2.55
- HOWL $0.60
- 52 Week High
- LTRN $7.21
- HOWL $5.73
- Technical
- Relative Strength Index (RSI)
- LTRN 61.32
- HOWL 56.29
- Support Level
- LTRN $3.80
- HOWL $0.80
- Resistance Level
- LTRN $4.43
- HOWL $1.07
- Average True Range (ATR)
- LTRN 0.33
- HOWL 0.09
- MACD
- LTRN 0.07
- HOWL 0.02
- Stochastic Oscillator
- LTRN 77.79
- HOWL 73.81
About LTRN Lantern Pharma Inc.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.